Trimel Pharmaceuticals Corporation (TSX:TRL) today reported financial results for the three and twelve month periods ended December 31, 2014, and provided an overview of its corporate highlights. Unless otherwise noted, all dollar amounts shown in this press release are in U.S. dollars.
“This past year was marked by a number of accomplishments for Trimel and tremendous progress made on many fronts. We licensed the U.S. rights for NATESTO™, the first product borne from our internal product development efforts, advanced our TEFINA™ clinical program, and acquired our first revenue generating asset in ESTRACE®.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
